Gaudium IVF has fixed its price band at ₹75 to ₹79 per equity share. The issue consists of a fresh issue of ₹90 crore (approx. 1.14 crore shares) and an Offer for Sale (OFS) of ₹75 crore (approx. 0.95 crore shares) by the promoter, Dr. Manika Khanna.
The company intends to use ₹50 crore of the fresh proceeds for a major expansion—establishing 19 new IVF centers across India to capitalize on the growing demand for fertility treatments. Another ₹20 crore will be used to repay existing debt. Financially, Gaudium has shown robust performance; its revenue grew 47% to ₹70.72 crore in FY25, with a significant 85% jump in Profit After Tax (PAT) to ₹19.13 crore. For the first half of the current fiscal (H1 FY26), it has already reported a PAT of ₹12.51 crore.
Today, the company is engaging with Anchor Investors (large institutional buyers). Their participation level will be revealed this evening and will serve as a key indicator of market confidence before the retail window opens on February 20.
Key IPO Details & Timetable
| Feature | Details |
|---|---|
| Price Band | ₹75 – ₹79 per share |
| Anchor Bidding | Today, February 18, 2026 |
| Public Open Date | February 20, 2026 (Friday) |
| Public Close Date | February 24, 2026 |
| Lot Size | 189 Shares (Min. Investment ₹14,931) |
| Total Issue Size | ₹165 Crore |
| Listing Platform | BSE & NSE (Mainboard) |
| Tentative Listing | February 27, 2026 |
Important News & Investor Insights
Today's Status (Feb 18): This is Anchor Day. Retail investors cannot bid yet, but should watch for the anchor allotment list tonight. If marquee funds like SBI MF or HDFC MF participate, it usually boosts retail sentiment for Friday.
Grey Market Premium (GMP): As of this morning, the GMP is trading at a modest ₹15, suggesting a potential 19% listing gain. This is a positive sign compared to the "flat" rumors seen earlier in the week.
"First Mover" Advantage: As the first pure-play IVF listing, Gaudium may attract a "scarcity premium." Analysts note that the Indian IVF market is expected to grow at 13% CAGR, yet only 2% of infertile couples currently seek treatment, leaving a massive untapped market.
Operational Risk: A key risk factor mentioned in the RHP is the company's heavy reliance on a limited number of embryologists. The loss of key medical personnel could directly impact their high success rates and revenue.
Valuation: At the upper price band, the IPO is valued at a P/E of approximately 23x (based on FY25 earnings). This is considered attractive and slightly lower than the broader healthcare industry average of 26x.
Loading comments...